ESC Heart & Brain Workshop

Workshop 3:

Anticoagulants and antiplatelet drugs

Sven Wassmann, MD, PhD, FESC Munich, Germany



Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced in any way by its sponsors.






















- 73 year old female
- Paroxysmal AF diagnosed 3 months ago
- Mild carotid plaques
- Aspirin 100 mg OD
- CrCl 65 ml/min
- CHA_2DS_2 -VASc = 2, HAS-BLED = 2 (1)



- 73 year old female
- Paroxysmal AF diagnosed 3 months ago
- Mild carotid plaques
- Arterial hypertension, BP 165/90 mmHg
- Aspirin 100 mg OD
- CrCl 65 ml/min
- CHA_2DS_2 -VASc = 3, HAS-BLED = 3 (2)

ESC Guidelines on Atrial Fibrillation 2016



AF = atrial fibrillation; LAA = left atrial appendage; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; VKA = vitamin K antagonist.

^aCongestive heart failure, Hypertension,Age ≥75 years (2 points), Diabetes, prior Sstroke/TIA/embolus (2 points), Vascular disease, age 65–74 years, female Sex.

^bIncludes women without other stroke risk factors.

^{&#}x27;IlaB for women with only one additional stroke risk factor.

dIB for patients with mechanical heart valves or mitral stenosis.

ESC Guidelines on Atrial Fibrillation 2016

Recommendations for stroke prevention in patients with atrial fibrillation Oral anticoagulation therapy to prevent thromboembolism is recommended for all male AF patients with a CHA2DS2-VASc Α score of 2 or more. Oral anticoagulation therapy to prevent thromboembolism is recommended in all female AF patients with a CHA2DS2-VASc Α score of 3 or more. CHA₂DS₂-VASc score of I, considering individual characteristics and patient preferences. Oral anticoagulation therapy to prevent thromboembolism should be considered in female AF patients with a lla В CHA₂DS₂-VASc score of 2, considering individual characteristics and patient preferences. Vitamin K antagonist therapy (INR 2.0-3.0 or higher) is recommended for stroke prevention in AF patients with В moderate-to-severe mitral stenosis or mechanical heart valves. When oral anticoagulation is initiated in a patient with AF who is eligible for a NOAC (apixaban, dabigatran, edoxaban, or Α rivaroxaban), a NOAC is recommended in preference to a Vitamin K antagonist. When patients are treated with a vitamin K antagonist, time in therapeutic range (TTR) should be kept as high as Α possible and closely monitored. AF patients already on treatment with a vitamin K antagonist may be considered for NOAC treatment if TTR is not well Ilb Α controlled despite good adherence, or if patient preference without contra-indications to NOAC (e.g. prosthetic valve).


Antiplatelet monotherapy is not recommended for stroke prevention in AF patients, regardless of stroke risk.

NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are not recommended in patients with mechanical heart valves (Level of evidence B) or moderate-to-severe mitral stenosis (Level of evidence C).

Phase 3 RCTs comparing NOAC vs Warfarin in AF: Comparison of Effect on Stroke and Bleeding




Major Bleeding



No head to head comparisons

Risk of Intracranial Bleeding in NOAC RCTs in Patients with Atrial Fibrillation




No head to head comparisons



- 73 year old female
- S/P mild ischemic stroke 2 weeks ago
- Diagnosis of paroxysmal AF at follow-up visit (3 day Holter ECG)
- Arterial hypertension, well-controlled
- Stable coronary artery disease with S/P stenting 2 years ago
- Aspirin 100 mg OD
- CrCl 65 ml/min
- CHA_2DS_2 -VASc = 6, HAS-BLED = 3 (2)


Representation of patients with previous stroke in the Phase 3 RCTs comparing NOAC vs Warfarin in AF



- 1. Connolly et al. N Engl J Med 2011;364:806-17; 2. Patel et al. New Engl J Med 2011;365:883-91;
- 3 . Granger et al. New Engl J Med 2011;365:981-92; 4. Giugliano et al. N Engl J Med 2013;369:2093-104;
- 5. Connolly et al. N Engl J Med 2011;364:806-17;

ARISTOTLE: Subgroup analysis of patients with or without previous stroke

Stroke or Systemic Embolism




No significant interactions for stroke or bleeding endpoints including ICH




- 73 year old female
- S/P mild ischemic stroke 3 months ago
- Paroxysmal AF, currently normal sinus rhythm
- Arterial hypertension, well-controlled
- Now acute coronary syndrome (NSTEMI), PCI of LAD with 2 DES
- Dabigatran 150 mg BID
- CrCl 65 ml/min
- CHA_2DS_2 -VASc = 6, HAS-BLED = 3

Anticoagulation and Platelet Inhibition In Patients with AF and PCI: RE-DUAL PCI



No significant difference for combined endpoint: death, MI, stroke, SE, unplanned revasc.

ESC Update on DAPT in CAD 2017: AF and PCI



^{1:} Periprocedural administration of aspirin and clopidogrel during PCI is recommended irrespective of the treatment strategy.

^{2:} High ischaemic risk is considered as an acute clinical presentation or anatomical/procedural features which might increase the risk for myocardial infarction.

^{3:} Bleeding risk can be estimated by HAS-BLED or ABC score.

Thank you for your attention!

Workshop 3:

Anticoagulants and antiplatelet drugs

Sven Wassmann, MD, PhD, FESC Munich, Germany



Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced in any way by its sponsors.

















